BioCentury
ARTICLE | Financial News

Merck KGaA spinout Calypso raises first tranche of €20M series A

February 22, 2019 7:15 PM UTC

Calypso Biotech B.V. (Amsterdam, the Netherlands) closed the first tranche of a €20 million ($22.6 million) series A round Feb. 20, with enough funding to begin clinical studies of its lead candidate to treat eosinophilic esophagitis.

The round was led by Gilde Healthcare Partners and INKEF Capital, who joined Johnson & Johnson Innovation - JJDC Inc. and founding investor M Ventures, the investment arm of Merck KGaA (Xetra:MRK)...

BCIQ Company Profiles

Calypso Biotech B.V.

Merck KGaA

BCIQ Target Profiles

Interleukin-15 (IL-15)